信息搜索
信息关键字：药
  
『查询2022年信息』  『查询2021年信息』  『查询2020年信息』  『查询2019年信息』  『查询2018年信息』  『查询2017年信息』  『查询2016年信息』
『查询2015年信息』  『查询2014年信息』  『查询2013年信息』  『查询2012年信息』  『查询2011年信息』  『查询2010年信息』  『查询2009年信息』

分页[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] [223] [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] [239]

·医药生物行业周报：珍惜配置医药的窗口期2023-10-31 0:52:15
·佛慈制药前三季度营收和净利均实现两位数增长2023-10-31 0:52:02
·医药行业周报：市场情绪回暖，精选个股2023-10-31 0:43:59
·医药生物行业周报：多重筑底，积极布局2023-10-30 22:49:53
·老百姓大药房第三季度归母净利润增超三成 “加盟+联盟”构建生态共赢2023-10-30 22:48:20
·医药生物行业周报：三季报业绩压力利空基本落地，建议关注超跌的业绩反转个股2023-10-30 22:32:00
· 56家上市公司被上百家机构调研 扎堆医药板块2023-10-30 21:10:15
·10月30日奥赛康涨停分析：创新药，幽门螺杆菌概念，医药概念热股2023-10-30 17:54:40
·恒瑞医药：与Merck Healthcare签署HRS-1167和SHR-A1904项目授权许可协议2023-10-30 16:47:36
·10月30日誉衡药业涨停分析：基因测序，PD1抑制剂，民营医院概念热股2023-10-30 16:41:07
·医药生物行业周报：关注具有长期投资价值公司的底部布局机会2023-10-30 15:19:02
·君实生物PD-1获FDA批准上市 国产创新药出海进入新阶段(附概念股)2023-10-30 13:32:22
·医药生物行业跟踪周报：医疗反腐艰难时刻已过，全面战略布局2024年2023-10-30 13:24:26
·海创药业：氘恩扎鲁胺制剂撤回流程预计将于未来2周内结束2023-10-30 13:10:25
·远大医药创新液体栓塞剂LavaTM在美国正式商业化 为外周动脉出血提供全新治疗手段2023-10-30 12:20:03
·国际市场成新增长点 翰宇药业前三季度海外营收同比增长超60%2023-10-30 12:08:24
·A股午评：创业板指高开高走半日涨2.33% 医药权重股再度走强2023-10-30 11:31:37
·突来利空，“民营商超第一股”将被ST！A股唯一抗蛇毒血清制品公司发布利好，董事长解除留置！中药价格异动引关注，低估值高增长股揭秘2023-10-30 11:15:00
·CRO概念大涨 九洲药业涨停2023-10-30 10:17:58
·突来利空，“民营商超第一股”将被ST！A股唯一抗蛇毒血清制品公司发布利好，董事长解除留置！中药价格异动引关注，低估值高增长股揭秘2023-10-30 9:01:35

分页[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] [223] [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] [239]